Trimi's 3 Medications: How to Choose Between Semaglutide, Tirzepatide, and Retatrutide

The weight loss medication landscape has expanded rapidly, and patients now face a decision that would have been unimaginable just a few years ago: which highly effective medication should I choose? Trimi provides access to the three most important GLP-1-based weight loss medications -- semaglutide, tirzepatide, and (once FDA-approved) retatrutide. Each represents a different generation of incretin therapy, with distinct mechanisms, efficacy profiles, and ideal patient populations.

Choosing the right medication is not simply about selecting the newest or most potent option. It requires considering your health profile, treatment goals, budget, risk tolerance, and the specific comorbidities you may have. This guide walks you through the decision, with honest assessments of each medication's strengths and limitations.

Side-by-Side Comparison

Semaglutide: The Proven Performer

Semaglutide remains the most prescribed and best-studied GLP-1 medication for weight loss. It is the gold standard against which all other obesity medications are measured. For patients who are new to GLP-1 therapy, it offers a well-understood, proven starting point with the longest track record of safety and efficacy.

The SELECT trial's demonstration of 20% cardiovascular event reduction gives semaglutide a unique advantage that no other obesity medication currently matches. For patients with established cardiovascular disease or high cardiovascular risk, this proven benefit may outweigh the additional weight loss potential of newer medications.

From a practical standpoint, compounded semaglutide is typically the most affordable entry point into GLP-1 therapy, making it accessible to patients who might not be able to afford brand-name or newer medications.

Tirzepatide: The Step Up

Tirzepatide's dual-agonist mechanism (GLP-1 + GIP) consistently produces 5-7 percentage points more weight loss than semaglutide in clinical trials. For a 250-pound patient, that difference translates to approximately 12-17 additional pounds lost -- clinically meaningful for health outcomes.

Tirzepatide's advantage is most pronounced in patients with type 2 diabetes, where its superior insulin sensitization through GIP receptor activation produces both better glucose control and better weight loss than semaglutide. In the SURPASS head-to-head trial, tirzepatide outperformed semaglutide on both endpoints.

For patients who have been on semaglutide and reached a plateau, tirzepatide offers a natural upgrade path. The additional GIP receptor activity provides a new mechanism that can restart weight loss in patients who have stopped responding to GLP-1-only therapy.

Retatrutide: The Next Generation (Coming Soon)

Retatrutide represents the cutting edge of incretin-based therapy. By adding glucagon receptor activation to GLP-1 and GIP, it introduces the ability to increase energy expenditure -- the first weight loss medication to meaningfully address both sides of the energy balance equation. Learn more about the glucagon receptor pathway and how it enhances weight loss.

The Phase 2 data showing 24% average weight loss and 86% liver fat reduction positions retatrutide as potentially transformative, particularly for patients with fatty liver disease. However, it is important to note that retatrutide's safety profile is less well-characterized than semaglutide or tirzepatide, and the glucagon component introduces additional monitoring requirements.

For the latest on retatrutide's development timeline, read our TRIUMPH trials breakdown.

How to Choose: A Decision Framework

Start with Your Health Profile

• Type 2 diabetes? Tirzepatide has the strongest head-to-head evidence for combined weight loss and glucose control.
• Cardiovascular disease or high CV risk? Semaglutide has proven cardiovascular outcomes data (SELECT trial). Consider this advantage seriously.
• Fatty liver disease (NAFLD/MASH)? Current options: tirzepatide offers better liver fat reduction than semaglutide. Future option: retatrutide may be significantly more effective once approved.
• No specific comorbidities? Either semaglutide or tirzepatide is appropriate. Cost and personal preference may guide the decision.

Consider Your Weight Loss Goals

• Need to lose 10-15% body weight: Semaglutide will likely achieve this for most patients and offers the best value.
• Need to lose 15-20% body weight: Tirzepatide provides higher probability of reaching this goal.
• Need to lose 20%+ body weight: Tirzepatide at higher doses, or retatrutide when available, may be necessary. Consider also that lifestyle integration significantly affects outcomes with any medication.

Factor in Practical Considerations

• Budget: Compounded semaglutide offers the most affordable access. Brand-name tirzepatide is more expensive. Retatrutide pricing is unknown but likely premium at launch.
• Insurance: Coverage varies significantly by plan and medication. Some insurers cover one medication but not another. Check your specific plan's formulary.
• Risk tolerance: Semaglutide has the most extensive safety record. Tirzepatide's record is growing rapidly. Retatrutide's record is limited to clinical trials.
• Availability: Supply constraints have periodically affected both semaglutide and tirzepatide. Compounded versions typically have more stable availability.

The Trimi Approach

At Trimi, medication selection is a collaborative process between you and your provider. Here is how it works:

1. Comprehensive evaluation: Your Trimi provider reviews your medical history, current health conditions, previous weight loss attempts, and treatment goals.
2. Personalized recommendation: Based on your profile, your provider recommends the medication most likely to meet your goals safely and effectively.
3. Ongoing optimization: Through regular check-ins, your provider monitors progress, manages side effects, and adjusts treatment as needed -- including switching medications if your current option is not meeting your goals.
4. Forward planning: As new options become available (including retatrutide), your provider can help you evaluate whether transitioning makes sense for your situation.

Visit our treatments page for detailed information about currently available medications, or learn how the Trimi treatment process works.